AudioCure Pharma GmbH, a Berlin, Germany-based start up focused on the clinical development of drug candidates in neurodegenerative disease indications, has raised a seed financing of undisclosed amount.
Backers include High-Tech Gründerfonds and business angel Dr. Schumacher.
The company intends to use the company to develop its lead compound in the preclinical phase. AudioCure Pharma’s lead candidate is a small molecule compound for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear.
The company was founded in 2010 by university professor and doctor of medicine Hans Rommelspacher. Along with NanoPet Pharma Berlin and Wildau Technical University of Applied Sciences, AudioCure Pharma created the NeuroPro Alliance research network.